ATE349523T1 - Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten - Google Patents

Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten

Info

Publication number
ATE349523T1
ATE349523T1 AT01977082T AT01977082T ATE349523T1 AT E349523 T1 ATE349523 T1 AT E349523T1 AT 01977082 T AT01977082 T AT 01977082T AT 01977082 T AT01977082 T AT 01977082T AT E349523 T1 ATE349523 T1 AT E349523T1
Authority
AT
Austria
Prior art keywords
human
related polypeptide
treat diseases
diseases
immunodeficiencies
Prior art date
Application number
AT01977082T
Other languages
English (en)
Inventor
Andrew Lawrence Glasebrook
Ling Liu
Christy Michelle Newton
Jonathan Wendell Tetreault
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26933217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE349523(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE349523T1 publication Critical patent/ATE349523T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01977082T 2000-10-13 2001-09-28 Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten ATE349523T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24017700P 2000-10-13 2000-10-13
US30993601P 2001-08-03 2001-08-03

Publications (1)

Publication Number Publication Date
ATE349523T1 true ATE349523T1 (de) 2007-01-15

Family

ID=26933217

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01977082T ATE349523T1 (de) 2000-10-13 2001-09-28 Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten

Country Status (7)

Country Link
US (1) US20060083713A1 (de)
EP (1) EP1326974B1 (de)
AT (1) ATE349523T1 (de)
AU (1) AU2001296229A1 (de)
DE (1) DE60125563T2 (de)
ES (1) ES2277947T3 (de)
WO (1) WO2002033083A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU740405B2 (en) * 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP3112468A1 (de) * 1998-05-15 2017-01-04 Genentech, Inc. Il-17-homologe polypeptide und therapeutische verwendung davon
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7314623B2 (en) * 2002-07-15 2008-01-01 Wyeth Methods and compositions for modulating T helper (Th) cell development and function
EP2784084B2 (de) 2003-07-08 2023-10-04 Novartis Pharma AG Heterologe IL-17A/F-Polypeptide und deren therapeutische Verwendungen
EP1670501A2 (de) * 2003-09-25 2006-06-21 ZymoGenetics, Inc. Verfahren zur behandlung von autoimmunkrankheiten mit il-21
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP1671642A1 (de) 2004-12-15 2006-06-21 Universite D'angers Zusammensetzungen mit (Ant)agonisten von Oncostatin M (OSM), IL-31 und IFN-gamma zur Modulierung der Migration und Funktion von Keratinozyten via einen Rezeptor welcher OSMRbeta als Untereinheit enthält, und entprechende Anwendungen
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
EP2170306A1 (de) * 2007-06-26 2010-04-07 Lexicon Pharmaceuticals, Inc. Verfahren zur behandlung von serotonin-vermittelten erkrankungen und störungen
RU2474588C2 (ru) 2008-05-05 2013-02-10 Новиммун Са Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
EP2432493A1 (de) * 2009-05-20 2012-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Verwendung von il-17-polypeptiden zur verwendung bei der prävention oder behandlung von atherosklerose
US20130064788A1 (en) * 2009-10-10 2013-03-14 Eleven Biotherapeutics, Inc. Il-17 family cytokine compositions and uses
US11135268B2 (en) * 2015-07-07 2021-10-05 Fred Hutchinson Cancer Research Center Compositions, kits, and methods using interleukin-17C to promote neural growth and/or neural survival
EP3452598A4 (de) 2016-05-06 2020-04-29 Exicure, Inc. Konstrukte aus liposomaler sphärischer nukleinsäure (sna) mit antisense-oligonukleotiden (aso) zum spezifischen knockdown von interleukin-17-rezeptor-mrna
CN106153923B (zh) * 2016-06-21 2017-12-05 北京大学第一医院 预测谷丙转氨酶小于二倍正常上限的慢性乙型病毒性肝炎患者肝脏炎症程度的系统
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU740405B2 (en) * 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP1082433A4 (de) * 1998-05-29 2003-01-02 Human Genome Sciences Inc Interleukine 21 und 22
AU6277799A (en) * 1998-10-02 2000-04-26 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and usesthereof
ES2380812T3 (es) * 1999-12-23 2012-05-18 Genentech, Inc. Polipéptidos homólogos a IL-17 y usos terapéuticos de los mismos
AR028210A1 (es) * 2000-02-08 2003-04-30 Amgen Inc Molcculas semejantes a il-17 y usos de las mismas
AU2001272968C1 (en) * 2000-06-22 2008-06-05 Amgen Inc. Il-17 molecules and uses thereof
ES2349312T3 (es) * 2000-07-27 2010-12-29 Wyeth Llc Uso de anticuerpos antagonistas del receptor de il-10 para inhibir la inducción por il-tif/il-21 de proteínas de fase aguda.

Also Published As

Publication number Publication date
EP1326974B1 (de) 2006-12-27
DE60125563D1 (de) 2007-02-08
DE60125563T2 (de) 2007-10-04
US20060083713A1 (en) 2006-04-20
WO2002033083A3 (en) 2003-03-06
ES2277947T3 (es) 2007-08-01
AU2001296229A1 (en) 2002-04-29
WO2002033083A2 (en) 2002-04-25
EP1326974A2 (de) 2003-07-16

Similar Documents

Publication Publication Date Title
ATE349523T1 (de) Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE552849T1 (de) Behandlungsverfahren unter verwendung von ctla-4 antikörpern
ATE282413T1 (de) Verwendung von tempol zur behandlung von essentiellem hochdruck
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
EE05075B1 (et) POL1212 aminohappej„rjestust kodeeriv DNA, seda sisaldav ekspressioonivektor, sea modifitseeritud VIII-tegur, sellel p?hinev ravimkompositsioon ning meetod sea modifitseeritud VIII-teguri aminohappej„rjestust omava valgu valmistamiseks
CY1111120T1 (el) Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE267607T1 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
ATE230417T1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
DK1151009T3 (da) Antimikrobielt/endotoksin-neutraliserende polypeptid
DE69929464D1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
DE60331546D1 (de) Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung
DE60319083D1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
ATE421329T1 (de) Verwendung von aplidine zur behandlung von kardiovaskulären erkrankungen
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
DE60140960D1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
ATE180277T1 (de) Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
EP1143996A4 (de) Methode zur behandlung von chronischen herzerkrankungen
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
EA199900006A1 (ru) Препарат и способ для лечения застоной сердечной недостаточности

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties